Cite
HARVARD Citation
Gassart, A. et al. (n.d.). 442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy. Journal for immunotherapy of cancer. p. A468. [Online].